CFT 8919
Alternative Names: CFT-8919Latest Information Update: 20 Nov 2023
At a glance
- Originator C4 Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Proteolysis
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Brain metastases; Non-small cell lung cancer
Most Recent Events
- 01 Nov 2023 The China National Medical Products Administration (NMPA) accepts the Clinical Trial Application for review
- 08 Aug 2023 C4 Therapeutics plans to file an IND application for Non small cell lung cancer in first half of 2023
- 19 Jul 2023 C4T Therapeutics plans to initiate for Non-small cell lung cancer clinical trial outside to Greater China